A5379: B-ENHANCEMENT OF HBV VACCINATION IN PERSONS LIVING WITH HIV (BEeHIVe): Evaluation of HEPLISAV-B
||Male and Female Patients
|U.S. Govt. ID:
||Anyelina Cantos: 646-856-1648 / firstname.lastname@example.org
This study is looking at hepatitis B virus (HBV) vaccination in adults 18 to 70 years of age living with HIV around the world. Hepatitis B is a serious viral infection that affects the liver and is transmitted through blood and body fluids. A vaccine (a shot of medicine given through a needle) can prevent HBV, but there is no cure. A new vaccine approved by the United States Food and Drug Administration (FDA), called HEPLISAV-B, has been shown to provide a better response in other people who have not responded well to the older HBV vaccines. The purpose of this study is to find out whether this vaccine, HEPLISAV-B, will prove to be more effective in adults living with HIV than the current standard, ENGERIX-B vaccine. There are two groups of individuals in this study, Group A and Group B. Group A, will include individuals who have received a previous HBV vaccination but did not respond well to the vaccine. Group B will include individuals who have never received a HBV vaccination. If you are in Group A, you have an equal chance of receiving either two shots of HEPLISAV-B, three shots of HEPLISAV-B, or three shots of ENGERIX-B (current standard HBV vaccine). If you are in Group B, you will receive three shots of HEPLISAV-B. You will be compensated for your time and travel.
Michael Yin, MD
|Are you between 18-70 years of age?
|Have you been diagnosed with HIV?